期刊文献+

沙利度胺对实验性关节炎大鼠滑膜细胞凋亡的影响 被引量:1

Effect of thalidomide on apoptosis of fibroblast-like synoviocytes in experimental arthritis rat
暂未订购
导出
摘要 目的研究不同浓度沙利度胺对体外培养成纤维细胞样滑膜细胞(FLS)凋亡的影响。方法体外培养及纯化FLS,分为6组:对照组,脂多糖(LPS)组,LPS+高剂量沙利度胺(50mg/L)组,LPS+中剂量沙利度胺(5mg/L)组,LPS+低剂量沙利度胺(0.5mg/L)组,LPS+甲氨蝶呤(MTX)组。48小时后显微镜及电镜观察不同处理组FLS形态,膜黏连蛋白-5/碘化丙啶(Annexin-Ⅴ/PI)联合标记法测定FLS凋亡率及坏死率。结果①原代滑膜细胞培养3代后以梭形且呈极向排列FLS为主;②沙利度胺及MTX处理后FLS渐呈不规则形,细胞变圆缩小,透射电镜下可见典型细胞凋亡。③中、高剂量沙利度胺及MTX组凋亡率和坏死率均高于对照组、LPS组及低剂量沙利度胺组,凋亡率分别为(5.72±1.42)%、(8.07±1.45)%、(11.28±2.48)%vs(0.30±0.09)%、(0.24±0.05)%、(0.40±0.04)%(P<0.05),坏死率分别为(12.96±4.32)%、(20.34±4.43)%、(18.11±1.17)%vs(0.22±0.08)%、(0.13±0.09)%、(1.94±1.16)%(P<0.05);低、中、高剂量沙利度胺及MTX组凋亡率均依次升高(P<0.05);低、中、高剂量沙利度胺组及MTX组坏死率均依次升高(P<0.05);高剂量沙利度胺组与MTX组坏死率之间比较差异无统计学意义(P>0.05)。结论沙利度胺能够诱导FLS凋亡,在一定浓度范围内该作用呈剂量依赖性。沙利度胺对FLS早期凋亡作用弱于MTX,对晚期凋亡作用与MTX相同。 Objective To investigate the effect of thalidomide in different dosages on apoptosis of fibroblast-like synoviocytes(FLS) cultured in vitro in the experimental arthritis rats.Methods The FLS were successfully cultured and purified in vitro from the synovial membrane tissues of the experimental arthritis rats,and the cells were divided into six groups as following:control group,lipopolysaccharide(LPS) group,LPS with high dosage of thalidomide(50 mg/L) group,LPS with middle dosage of thalidomide(5 mg/L) group,LPS with low dosage of thalidomide(0.5 mg/L) group and methotrexate(MTX) group.The morphological characteristics of FLS were observed by convert microscope and transmission electron microscope,and the apoptosis and necrosis rates were determined by flow cytometry after 48 hours.Results ①The original synovial cells tended to be spindle-shaped cells with good cell homogeneity after the third passage;② FLS changed to anomalistic form with smaller size,and cell apoptosis was distinct by the transmission electron microscope;③ The apoptosis and necrosis rates of the middle and high dosage of thalidomide group and MTX group were all higher than those of control group,LPS group and low dosage of thalidomide group(P0.05).The apoptosis rates were(5.72±1.42)%,(8.07±1.45)%,(11.28±2.48)% vs(0.30±0.09)%,(0.24±0.05)%,(0.40±0.04)%(P0.05) and the necrosis rates were(12.96±4.32)%,(20.34±4.43)%,(18.11±1.17)% vs(0.22±0.08)%,(0.13±0.09)%,(1.94±1.16)%(P0.05),respectively.The apoptosis rates of the low,middle and high dosage of thalidomide group and MTX group increased in turn(P0.05) and the same results were verified in the necrosis rates of the low,middle and high dosage of thalidomide group.Compared with MTX group,there was no difference in the necrosis rates in high dosage of thalidomide group(P0.05).Conclusion Thalidomide could induce FLS apoptosis partly in a dose-dependent manner,and it functions the same as MTX in late apoptosis but not better in earlier apoptosis than MTX.
出处 《临床荟萃》 CAS 2012年第10期865-868,F0003,共5页 Clinical Focus
关键词 关节炎 实验性 滑膜 细胞凋亡 沙利度胺 arthritis experimental synovial membrane apoptosis thalidomide
  • 相关文献

参考文献14

  • 1Maeda T,Hirayama M,Kobayashi D,et al.Mechanism of theregulation of organic cation/carnitine transporter 1(SLC22A4)by rheumatoid arthritis-associated transcriptionalfactor RUNX1and inflammatory cytokines[J].Drug MetabDispos,2007,35(3):394-401.
  • 2Pap T,van der Laan WH,Aupperle KR,et al.Modulation offibroblast-mediated cartilage degradation by articularchondrocytes in rheumatoid arthritis[J].Arthritis Rheum,2000,43(11):2531-2536.
  • 3Kim WU,Kang SS,Yoo SA,et al.Interaction of vascularendothelial growth factor 165 with neuropilin-1 protectsrheumatoid synoviocytes from apoptotic death by regulatingBcl-2expression and Bax translocation[J].J Immunol,2006,177(8):5727-5735.
  • 4王斌,陈敏珠,徐叔云.大鼠滑膜细胞的分离和培养[J].中国药理学通报,1994,10(1):73-74. 被引量:48
  • 5Edwards JC.Fibroblast biology.Development anddifferentiation of synovial fibroblasts in arthritis[J].ArthritisRes,2002,2(5):344-347.
  • 6Alvaro-Gracia JM,Yu C,Zvaifler NJ,et al.Mutual antagonismbetween interferon-gamma and tumor necrosis factor-alpha onfibroblast-like synoviocytes:paradoxical induction of IFN-gamma and TNF-alpha receptor expression[J].J ClinImmunol,1993,13(3):212–218.
  • 7Davis LS.A question of transformation:the synovial fibroblastin rheumatoid arthritis[J].Am J Pathol,2003,162(5):1399-1402.
  • 8Highton J,Hessian PA,Kean A,et al.Cell death by apoptosisis a feature of the rheumatoid nodule[J].Ann Rheum Dis,2003,62(1):77-80.
  • 9Morel J,Audo R,Hahne M,et al.Tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)induces rheumatoidarthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Ak[J].J Biol Chem,2005,280(16):15709-15718.
  • 10Ospelt C,Neidhart M,Gay RE,et al.Synovial activation inrheumatoid arthritis[J].Front Biosci,2004,9:2323-2334.

二级参考文献8

  • 1Taylor PC. Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology, 2005, 44: 721-728.
  • 2Cha HS, Bae EK, Koh JH, et al. Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes. J Rheumatol, 2007, 34: 16-19.
  • 3Lainer DT, Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs, 2005, 14: 1-17.
  • 4Du W, Hattori Y, Hashiguchi A, et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int, 2004, 54: 285-294.
  • 5Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr, 2004, 145: 856-857.
  • 6Li X, Liu X, Wang J, et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res, 2003, 23: 2481-2487.
  • 7Yabu T, Tomimoto H, Taguchi Y, et al. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood, 2005, 106: 125-134.
  • 8刘爱京,潘崚,王崇,刘曦,邵福灵,靳洪涛,刘晓雷.沙利度胺影响实验性关节炎大鼠肿瘤坏死因子-α及血红蛋白的研究[J].中华风湿病学杂志,2008,12(1):39-44. 被引量:4

共引文献50

同被引文献17

  • 1Belani CP,Fossella F. Elderly subgroup analysis of arandomized phase Iff study of docetaxel plus platinumcombinations versus vinorelbine plus cisplatin for first-linetreatment of advanced nonsmall cell lung carcinoma (TAX326)[J]. Cancer,2005,104(12):2766-2774.
  • 2Shao YY, Lin ZZ, Hsu C, et al. Efficacy, safety, and potentialbiomarkers of thalidomide plus metronomic chemotherapy foradvanced hepatocellular carcinoma[J]. Oncology,2012,82 (1):59-66.
  • 3Alexander BM,Wang M, Yung WK,et al. A phase H study ofconventional radiation therapy and thalidomide forsupratentorial, newly-diagnosed glioblastoma ( RTOG 9806 )[J]. J Neurooncol,2013,111(1); 33-39.
  • 4Maeda A,Nakata M, Yasuda K, et al. Influence of vascularendothelial growth factor single nucleotide polymorphisms onnon-small cell lung cancer tumor angiogenesis[J3. Oncol Rep,2013,29(1):39-44.
  • 5Verheul HM, Panigrahy D,Yuan J, et al. Combination oralantiangiogenic therapy with thalidomide and sulindac inhibitstumour growth in rabbits [J]. Br J Cancer,1999,79 (1 ) : 114-118.
  • 6Jazieh AR,Komrokji R, Gupta A, et al. Phase fl trial ofthalidomide.irinotecan and gemcitabine in chemonaive patientswith advanced non-small cell lung cancer [J]. Cancer Invest,2009,27(9):932-936.
  • 7Zidi I’Mestiri S,Bartegi A,et aL.TNF-alpha and its inhibitor incancer [J]. Med Oncol,2010,27(2) ; 185-198.
  • 8Lee SM, Rudd R,Woll PJ, et al. Randomized ,double-blindplacebo-controlled trial of thalidomide in combination withgemcitabine and carboplatin in advanced non-small-cell lungcancer[J]. J Clin Oncol,2009,27(31) :5248-5254.
  • 9Eo WK,Kim SH, Cheon SH, et al. Toxic epidermal necrolysisfollowing thalidomide and dexamethasone treatment formultiple myeloma: a case report [J]. Ann Hematol, 2010, 89(4):421-422.
  • 10Vilas-Boas F,Goncalves R,Sobrinho Simoes M,et al.Thalidomide-induced acute cholestatic hepatitis:case report andreview of the literature [J]. Gastroenterol Hepatol, 2012,35(8):560-566.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部